

# Dominique Roulot

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7624796/publications.pdf>

Version: 2024-02-01

112  
papers

7,327  
citations

57631

44  
h-index

54797

84  
g-index

116  
all docs

116  
docs citations

116  
times ranked

6997  
citing authors

#	ARTICLE	IF	CITATIONS
1	Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites: a randomized trial. <i>Journal of Hepatology</i> , 1996, 25, 135-144.	1.8	425
2	Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications. <i>Gastroenterology</i> , 2017, 152, 142-156.e2.	0.6	420
3	Liver stiffness values in apparently healthy subjects: Influence of gender and metabolic syndrome. <i>Journal of Hepatology</i> , 2008, 48, 606-613.	1.8	372
4	Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: Results of a longitudinal study. <i>Hepatology</i> , 2015, 61, 660-667.	3.6	364
5	Diagnosis of Hepatic Fibrosis and Cirrhosis by Transient Elastography in HIV/Hepatitis C Virus-Coinfected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006, 41, 175-179.	0.9	323
6	In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: A potential new therapy for hepatic fibrosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999, 96, 12719-12724.	3.3	318
7	Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: A randomized trial comparing 3- and 6-month periodicities. <i>Hepatology</i> , 2011, 54, 1987-1997.	3.6	309
8	Transforming growth factor $\beta^2$ and the liver. <i>Hepatology</i> , 2001, 34, 859-867.	3.6	307
9	Transient elastography as a screening tool for liver fibrosis and cirrhosis in a community-based population aged over 45 years. <i>Gut</i> , 2011, 60, 977-984.	6.1	272
10	Molecular Phylogenetic Analyses Indicate a Wide and Ancient Radiation of African Hepatitis Delta Virus, Suggesting a Deltavirus Genus of at Least Seven Major Clades. <i>Journal of Virology</i> , 2004, 78, 2537-2544.	1.5	215
11	Norfloxacin primary prophylaxis of bacterial infections in cirrhotic patients with ascites: a double-blind randomized trial. <i>Journal of Hepatology</i> , 1998, 29, 430-436.	1.8	192
12	Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs. <i>Gastroenterology</i> , 2018, 155, 1436-1450.e6.	0.6	183
13	HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis. <i>Journal of Viral Hepatitis</i> , 2011, 18, e516-e522.	1.0	152
14	Nadolol for prophylaxis of gastrointestinal bleeding in patients with cirrhosis. <i>Journal of Hepatology</i> , 1988, 7, 118-125.	1.8	138
15	Liver stiffness diminishes with antiviral response in chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 656-663.	1.9	113
16	Vascular involvement of the liver in Turner's syndrome. <i>Hepatology</i> , 2004, 39, 239-247.	3.6	110
17	Role of transforming growth factor $\beta$ type II receptor in hepatic fibrosis: Studies of human chronic hepatitis C and experimental fibrosis in rats. <i>Hepatology</i> , 1999, 29, 1730-1738.	3.6	107
18	Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases. <i>Hepatology</i> , 2022, 75, 219-228.	3.6	107

#	ARTICLE	IF	CITATIONS
19	Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection. <i>Journal of Viral Hepatitis</i> , 2007, 14, 460-467.	1.0	105
20	Transient elastography for screening of liver fibrosis: Cost-effectiveness analysis from six prospective cohorts in Europe and Asia. <i>Journal of Hepatology</i> , 2019, 71, 1141-1151.	1.8	104
21	Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy. <i>Gastroenterology</i> , 2019, 156, 997-1009.e5.	0.6	100
22	Insulin resistance, serum leptin, and adiponectin levels and outcomes of viral hepatitis C cirrhosis. <i>Journal of Hepatology</i> , 2010, 53, 827-833.	1.8	96
23	Turner syndrome and pregnancy: clinical practice. Recommendations for the management of patients with Turner syndrome before and during pregnancy. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2010, 152, 18-24.	0.5	96
24	Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir). <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 54</i>	3.6	96
25	Genetic diversity and worldwide distribution of the deltavirus genus: A study of 2,152 clinical strains. <i>Hepatology</i> , 2017, 66, 1826-1841.	3.6	94
26	Randomized trial of leuprorelin and flutamide in male patients with hepatocellular carcinoma treated with tamoxifen. <i>Hepatology</i> , 2004, 40, 1361-1369.	3.6	93
27	Phylogenetic analyses confirm the high prevalence of hepatitis C virus (HCV) type 4 in the Seine-Saint-Denis district (France) and indicate seven different HCV-4 subtypes linked to two different epidemiological patterns. <i>Journal of General Virology</i> , 2001, 82, 1001-1012.	1.3	91
28	Estimate of hepatocellular carcinoma incidence in patients with alcoholic cirrhosis. <i>Journal of Hepatology</i> , 2018, 69, 1274-1283.	1.8	86
29	Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study. <i>Gastroenterology</i> , 2018, 155, 431-442.e10.	0.6	81
30	Low Accuracy of FIB-4 and NAFLD Fibrosis Scores for Screening for Liver Fibrosis in the Population. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2567-2576.e6.	2.4	80
31	Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis delta. <i>Journal of Hepatology</i> , 2020, 73, 1046-1062.	1.8	79
32	Treatment of severe alcoholic hepatitis by infusion of insulin and glucagon: A multicenter sequential trial. <i>Hepatology</i> , 1992, 15, 76-81.	3.6	78
33	Concordance in a World without a Gold Standard: A New Non-Invasive Methodology for Improving Accuracy of Fibrosis Markers. <i>PLoS ONE</i> , 2008, 3, e3857.	1.1	75
34	Nomogram for individualized prediction of hepatocellular carcinoma occurrence in hepatitis C virus cirrhosis (ANRS CO12 CirVir). <i>Hepatology</i> , 2016, 64, 1136-1147.	3.6	75
35	Rheumatologic manifestations of chronic hepatitis C infection. <i>Joint Bone Spine</i> , 2006, 73, 633-638.	0.8	74
36	Liver involvement in Turner syndrome. <i>Liver International</i> , 2013, 33, 24-30.	1.9	68

#	ARTICLE	IF	CITATIONS
37	Concomitant screening for liver fibrosis and steatosis in French type 2 diabetic patients using Fibroscan. <i>Liver International</i> , 2017, 37, 1897-1906.	1.9	68
38	Effect of Long-term Propranolol Treatment on Hepatocellular Carcinoma Incidence in Patients with HCV-Associated Cirrhosis. <i>Cancer Prevention Research</i> , 2012, 5, 1007-1014.	0.7	66
39	Randomized comparative multicenter study of hydroxyethyl starch versus albumin as a plasma expander in cirrhotic patients with tense ascites treated with paracentesis. <i>European Journal of Gastroenterology and Hepatology</i> , 1998, 10, 5-10.	0.8	63
40	Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir). <i>Journal of Hepatology</i> , 2010, 51, 622-629.	6.1	59
41	Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy. <i>Journal of Medical Virology</i> , 2009, 81, 2029-2035.	2.5	56
42	Bulevirtide with or without pegIFN $\alpha$ for patients with compensated chronic hepatitis delta: From clinical trials to real-world studies. <i>Journal of Hepatology</i> , 2022, 77, 1422-1430.	1.8	54
43	Personalized surveillance for hepatocellular carcinoma in cirrhosis using machine learning adapted to HCV status. <i>Journal of Hepatology</i> , 2020, 73, 1434-1445.	1.8	52
44	Quantitative analysis of transforming growth factor $\beta$ 1 messenger RNA in the liver of patients with chronic hepatitis C: Absence of correlation between high levels and severity of disease. <i>Hepatology</i> , 1995, 21, 298-304.	3.6	50
45	Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patients. <i>American Heart Journal</i> , 2018, 198, 4-17.	1.2	49
46	Hyperkinetic circulatory syndrome in patients with presinusoidal portal hypertension. <i>Journal of Hepatology</i> , 1989, 9, 312-318.	1.8	46
47	Effect of Prolonged Interferon Therapy on the Outcome of Hepatitis C Virus-Related Cirrhosis: A Randomized Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 502-507.	2.4	45
48	Long-term sympathetic and hemodynamic responses to clonidine in patients with cirrhosis and ascites. <i>Gastroenterology</i> , 1992, 102, 1309-1318.	0.6	42
49	Performance Characteristics of a New Consensus Commercial Kit for Hepatitis D Virus RNA Viral Load Quantification. <i>Journal of Clinical Microbiology</i> , 2017, 55, 431-441.	1.8	37
50	Prevalence and clinical significance of nodular regenerative hyperplasia in liver biopsies. <i>Liver International</i> , 2016, 36, 1059-1066.	1.9	35
51	Cholangitis in the acquired immunodeficiency syndrome: report of two cases and review of the literature. <i>Gut</i> , 1987, 28, 1653-1660.	6.1	33
52	Low dose of nitroglycerin failed to improve splanchnic hemodynamics in patients with cirrhosis: Evidence for an impaired cardiopulmonary baroreflex function. <i>Hepatology</i> , 1989, 10, 93-97.	3.6	33
53	Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradication. <i>Hepatology</i> , 2018, 68, 1245-1259.	3.6	33
54	Reduction of portal pressure by acute administration of furosemide in patients with alcoholic cirrhosis. <i>Journal of Hepatology</i> , 1989, 9, 246-251.	1.8	32

#	ARTICLE	IF	CITATIONS
55	Hepatitis E virus-induced primary cutaneous CD30(+) T cell lymphoproliferative disorder. <i>Journal of Hepatology</i> , 2017, 67, 1334-1339.	1.8	32
56	A randomized controlled trial of ursodeoxycholic acid in patients with alcohol-induced cirrhosis and jaundice. <i>Hepatology</i> , 2003, 37, 887-892.	3.6	30
57	Mechanisms of a clonidine-induced decrease in portal pressure in normal and cirrhotic conscious rats. <i>Hepatology</i> , 1989, 10, 477-481.	3.6	26
58	Prevalence and Clinical Significance of K��pffer Cell Hyperplasia With Hemophagocytosis in Liver Biopsies. <i>American Journal of Surgical Pathology</i> , 2011, 35, 337-345.	2.1	26
59	Hemodynamic effects of a combination of clonidine and propranolol in conscious cirrhotic rats. <i>Canadian Journal of Physiology and Pharmacology</i> , 1989, 67, 1369-1372.	0.7	25
60	Identification of the <i>Rochalimaea henselae</i> 16S rRNA Sequence in the Liver of a French Patient with Bacillary Peliosis Hepatis. <i>Journal of Infectious Diseases</i> , 1992, 166, 1462-1463.	1.9	25
61	Serological and Molecular Diagnosis of Hepatitis Delta Virus Infection: Results of a French National Quality Control Study. <i>Journal of Clinical Microbiology</i> , 2014, 52, 1694-1697.	1.8	24
62	Effects of oxygen inhalation on tissue oxygenation in patients with cirrhosis. <i>Journal of Hepatology</i> , 1989, 9, 240-245.	1.8	23
63	Renal Hemodynamics in Patients with Cirrhosis: Relationship with Ascites and Liver Failure. <i>Nephron</i> , 1993, 65, 359-363.	0.9	22
64	Hepatic denervation alters hemodynamic response to hemorrhage in conscious rats. <i>Hepatology</i> , 1989, 10, 473-476.	3.6	19
65	Applicability and variability of liver stiffness measurements according to probe position. <i>World Journal of Gastroenterology</i> , 2009, 15, 3398.	1.4	19
66	Peripheral intrahepatic cholangiocarcinoma occurring in patients without cirrhosis or chronic bile duct diseases. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 94-98.	0.8	16
67	Non��virological factors are drivers of hepatocellular carcinoma in viro-suppressed hepatitis B cirrhosis: Results of ANRS CO��12 CirVir cohort. <i>Journal of Viral Hepatitis</i> , 2019, 26, 384-396.	1.0	16
68	Interferon gamma-secreting HCV-specific CD8+ T cells in the liver of patients with chronic C hepatitis: relation to liver fibrosis - ANRS HC EP07 study*. <i>Journal of Viral Hepatitis</i> , 2006, 13, 474-481.	1.0	15
69	Evolutionary history of hepatitis C virus genotype 5a in France, a multicenter ANRS study. <i>Infection, Genetics and Evolution</i> , 2011, 11, 496-503.	1.0	14
70	Turner syndrome: French National Diagnosis and Care Protocol (NDCP; National Diagnosis and Care) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5</i>	1.2	12
71	Variable In Vivo Hepatitis D Virus (HDV) RNA Editing Rates According to the HDV Genotype. <i>Viruses</i> , 2021, 13, 1572.	1.5	9
72	Low rate of hepatitis C virus (HCV) transmission within the family. <i>Journal of Hepatology</i> , 1992, 14, 409-410.	1.8	8

#	ARTICLE	IF	CITATIONS
73	965 IS LIVER STIFFNESS MEASUREMENT AN APPROPRIATE SCREENING METHOD TO DETECT LIVER FIBROSIS IN THE GENERAL POPULATION?. Journal of Hepatology, 2008, 48, S361.	1.8	8
74	Eating Patterns in Patients with Compensated Cirrhosis: A Case-Control Study. Nutrients, 2018, 10, 60.	1.7	8
75	Successful treatment by mesocaval anastomosis of a common-bile-duct compression by choledochal varices. Journal of Hepatology, 1995, 23, 629-630.	1.8	7
76	Salvage liver transplantation for recurrent hepatocellular carcinoma after radiofrequency ablation: A new strategy?. Journal of Hepatology, 2012, 56, 14-16.	1.8	7
77	G08 : Incidence of hepatocellular carcinoma (HCC) and complications in alcoholic compensated cirrhosis. Preliminary results of a multicenter prospective French and belgian cohort (INCA Cirral). Journal of Hepatology, 2015, 62, S213-S214.	1.8	6
78	1254 RIBAVIRIN TREATMENT FOR CHRONIC HEPATITIS E: A CASE-SERIES. Journal of Hepatology, 2011, 54, S495.	1.8	5
79	P0600 : Predictive factors of cirrhosis, hepatic decompensation and hepatocellular carcinoma in patients with chronic hepatitis delta. Journal of Hepatology, 2015, 62, S541-S542.	1.8	5
80	Severe streptococcal cellulitis after subcutaneous pegylated interferon alfa-2B in a diabetic patient. Gastroenterologie Clinique Et Biologique, 2004, 28, 1294-1295.	0.9	4
81	Hepatic disease in Turner syndrome. International Congress Series, 2006, 1298, 146-151.	0.2	4
82	Risks factors of liver fibrosis in a cohort of intravenous drug users coinfectd with HIV and HCV at the HAART era: the role of mixed steatosis. Gastroenterologie Clinique Et Biologique, 2007, 31, 822-827.	0.9	4
83	Comprehensive Analysis of Hepatitis Delta Virus Assembly Determinants According to Genotypes: Lessons From a Study of 526 Hepatitis Delta Virus Clinical Strains. Frontiers in Microbiology, 2021, 12, 751531.	1.5	4
84	Quantitative analysis of transforming growth factor ?1 messenger RNA in the liver of patients with chronic hepatitis C: Absence of correlation between high levels and severity of disease*1. Hepatology, 1995, 21, 298-304.	3.6	3
85	615 PROSPECTIVE EVALUATION OF LIVER STIFFNESS DYNAMICS DURING AND AFTER PEGINTERFERON ALPHA-RIBAVIRIN TREATMENT IN PATIENTS WITH CHRONIC HEPATITIS C. Journal of Hepatology, 2009, 50, S226.	1.8	3
86	New Recommendations of Baveno Vi Conference for the Screening of Portal Hypertension: An Independent Sequential Validation in Patients with Compensated Viral Cirrhosis Taking into Account Virological Status (Anrs Co12 Cirvir Cohort). Journal of Hepatology, 2016, 64, S178.	1.8	3
87	Evolution of Hepatitis C Virus Treatment During the Era of Sofosbuvir-Based Therapies: A Real-World Experience in France. Digestive Diseases and Sciences, 2021, 66, 881-898.	1.1	3
88	793 DYNAMICS OF LIVER STIFFNESS DURING PEGINTERFREON ALPHA-RIBAVIRIN TREATMENT IN PATIENTS WITH CHRONIC HEPATITIS C. Journal of Hepatology, 2008, 48, S296.	1.8	2
89	219 LIVER STIFFNESS MEASUREMENT: AN APPROPRIATE SCREENING METHOD TO DETECT LIVER FIBROSIS IN THE GENERAL POPULATION. Journal of Hepatology, 2009, 50, S89.	1.8	2
90	Prospective Evidence That Hepatocellular Carcinoma Surveillance in Patients with Compensated Viral Cirrhosis Increases the Probability of Curative Treatment and Survival Taking into Account Lead-Time Bias (Anrs Co12 Cirvir Cohort). Journal of Hepatology, 2016, 64, S194-S195.	1.8	2

#	ARTICLE	IF	CITATIONS
91	Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 302-309.	0.8	2
92	Non-invasive diagnosis and follow-up of chronic infection with hepatitis B virus. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2022, 46, 101773.	0.7	2
93	ABO blood group does not influence Child-Pugh A cirrhosis outcome: An observational study from CIRRAL and ANRS CO12 CIRVIR cohorts. <i>Liver International</i> , 2022, 42, 1386-1400.	1.9	2
94	Hemodynamic effects of dopamine in conscious rats with secondary biliary cirrhosis. <i>Journal of Hepatology</i> , 1990, 11, 257-262.	1.8	1
95	Liver involvement in turner syndrome. <i>Journal of Hepatology</i> , 2002, 36, 160.	1.8	1
96	367 Molecular phylogenetic analyses indicate a wide and ancient radiation of African hepatitis delta virus suggesting a deltavirus genus to be composed of at least seven major clades. <i>Journal of Hepatology</i> , 2004, 40, 110.	1.8	1
97	550 Progression and severity of liver fibrosis in HIV-HCV co-infected patients with normal CD4 cell count: Comparison with HCV-infected patients. <i>Journal of Hepatology</i> , 2006, 44, S205.	1.8	1
98	High Frequency of X Chromosome Abnormalities in Women With Short Stature and Elevated Liver Enzymes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E1592-E1596.	1.8	1
99	P0328 : Incidence, characteristics and determinants of primary liver cancer occurring during surveillance of compensated HCV cirrhosis according to sustained virological response (ANRS CO12) Tj ETQq1 1 0.784314 rgBT /Over	1.8	1
100	P0579 : Epidemiological, clinical and virological features of hepatitis delta virus infection in France. <i>Journal of Hepatology</i> , 2015, 62, S532-S533.	1.8	1
101	Molecular diversity of HBV and HDV amino-acid sequences involved in HDV virion morphogenesis according to HBV and HDV genotypes: study of 1590 clinical strains. <i>Journal of Hepatology</i> , 2018, 68, S783-S784.	1.8	1
102	Screening for Liver Fibrosis in General or At-Risk Populations Using Transient Elastography. , 2020, , 545-550.		1
103	HCV infection screening and treatment in drug users followed in an addiction out patient unit. <i>Journal of Hepatology</i> , 2002, 36, 109.	1.8	0
104	649 high frequency of X chromosome abnormalities in short stature women with unexplained elevated liver enzymes. <i>Journal of Hepatology</i> , 2006, 44, S240-S241.	1.8	0
105	[597] EVOLUTION OF LIVER STIFFNESS MEASUREMENT DURING ANTIVIRAL THERAPY IN PATIENTS WITH CHRONIC HEPATITIS C. <i>Journal of Hepatology</i> , 2007, 46, S226.	1.8	0
106	446 REDUCED HEPATIC EXPRESSION OF PERFORIN AND GRANZYME B IN PATIENTS WITH HEMOPHAGOCYTIC SYNDROME. <i>Journal of Hepatology</i> , 2008, 48, S170.	1.8	0
107	401 LIVER STIFFNESS DYNAMICS IN HCV-INFECTED PATIENTS WITH AND WITHOUT AN SVR TO PEGINTERFERON ALPHA-RIBAVIRIN TREATMENT. FINAL RESULTS OF A PROSPECTIVE STUDY. <i>Journal of Hepatology</i> , 2010, 52, S164.	1.8	0
108	643 IMPROVED EFFICIENCY OF HCC SCREENING IS MAINLY DUE TO THE INTRODUCTION OF RFA AS THE FIRST LINE CURATIVE TREATMENT. <i>Journal of Hepatology</i> , 2011, 54, S260.	1.8	0

#	ARTICLE	IF	CITATIONS
109	112 INCIDENCE AND PREDICTIVE FACTORS OF HEPATOCELLULAR CARCINOMA AND COMPLICATIONS IN HBV-OR HCV-RELATED COMPENSATED CIRRHOSIS. A MULTICENTER PROSPECTIVE COHORT IN 1653 PATIENTS (ANRS) <a href="#">Tj&amp;TQq1</a> <a href="#">b0.7843</a>		14
110	Extrahepatic Cancer is the Second Cause of Non Liver-Related Death in Patients with Compensated Viral Cirrhosis and is Associated with Viral Replication (ANRS CO12 CirVir Prospective Cohort). <i>Journal of Hepatology</i> , 2016, 64, S273.	1.8	0
111	The Benefits of Virosuppression on Progression of Portal Hypertension in Patients with Compensated Viral Cirrhosis (ANRS CO12 CirVir Cohort). <i>Journal of Hepatology</i> , 2016, 64, S655-S656.	1.8	0
112	Regression of a CD30-Positive Primary Cutaneous T-Cell Lymphoproliferation after Ribavirin Treatment of Chronic Hepatitis E Virus Infection. <i>Blood</i> , 2016, 128, 4898-4898.	0.6	0